Skip to content
  1. Home/
  2. Latest news/
  3. What you need to know about Johnson & Johnson’s 2019 fourth-quarter and full-year earnings report
FINAL LEDE- What You Need to Know About Johnson & Johnson's 2019 Fourth Quarter and Full-Year Earnings Report- Q4 Earnings 2019

What you need to know about Johnson & Johnson’s 2019 fourth-quarter and full-year earnings report

Check out this infographic breakdown of the company’s fourth quarter and annual earnings report, with key performance highlights from its pharmaceutical, consumer and medical devices businesses.

fourth-quarter-and-full-year-earnings-banner-0122.png

Johnson & Johnson shared financial information this morning about its fourth quarter and full-year performance in 2019.

Since its founding in 1886, the company has grown to become one of the world’s largest and most broadly based healthcare companies, with approximately 132,000 employees across the globe working every day to help change the trajectory of health for humanity.

“Johnson & Johnson’s 2019 results reflect a solid fourth quarter and full year of strong performance for the company,” says Joe Wolk, Executive Vice President and Chief Financial Officer, Johnson & Johnson. “Throughout 2019, the colleagues of Johnson & Johnson remained focused on executing growth strategies, investing in innovation and delivering transformative healthcare solutions to patients and consumers around the world. Looking ahead to 2020, I am confident that our broad-based business is well positioned to drive strong results and deliver long-term value to all of our stakeholders.”

For more details about the company’s 2019 fourth quarter and full-year results, and to read a message from Chairman and Chief Executive Officer Alex Gorsky, here’s an infographic packed with key stats.


2019 EOY/Fourth Quarter Earnings infographic

Johnson & Johnson’s 2019 Earnings

Read the earnings press release, which includes fourth quarter and full-year financial data for 2019.

Want to see more company earnings information? Find several years of Johnson & Johnson quarterly and full-year results here.


More from Johnson & Johnson

Inside Johnson & Johnson’s decades-long quest to develop effective treatments for IBD

Inflammatory bowel disease doesn’t have a cure—yet. But the recent FDA approval of a promising medication is the latest in a long line of treatments from Johnson & Johnson that are helping patients with IBD.

The future of immunology

Learn about the advances Johnson & Johnson is making to potentially help treat the millions of people living with conditions in which the immune system mistakenly damages healthy cells in the body.

Using your own cells to fight cancer

Cell therapy is bringing the world one step closer to eliminating cancer. Here’s how Johnson & Johnson is moving this cutting-edge therapy forward.